...donors. Promethera has four hepatic programs -- two cell therapies developed in-house, another acquired from Cytonet GmbH & Co. KG...
...therapies. The mAb has anti-inflammatory effects in preclinical models. Promethera’s most advanced program, Heparesc from Cytonet...
...to change the company’s calculus. Although Promethera gained a facility in North Carolina through the Cytonet...

...Promethera acquired Cytonet’s “key” assets, including Heparesc . Promethera also will receive a U.S. Cytonet facility...
...product manufacturing and liver sourcing with a U.S. organ procurement organization. A team of seven Cytonet...
...and that Cytonet’s lead shareholder will receive up to a 13% equity stake in Promethera. Cytonet GmbH & Co. KG...

...data comparing Syn1010 with Ravicti. Gutiérrez-Ramos said cell therapies in the clinic require diet restrictions. Cytonet GmbH & Co. KG's...
...receiving HepaStem will be able to eat more proteins, but it still recommends low-protein diets. Cytonet...
...and Institutions Mentioned BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), San Rafael, Calif. Boston University , Boston, Mass. Cytonet GmbH & Co. KG...

...up front plus $140 million in milestones. Another innovator in registration from the cohort is Cytonet GmbH & Co. KG...
...treat pediatric urea cycle disorders (UCD). Promethera Biosciences S.A. is a couple of years behind Cytonet...
...Germany Cardiorentis AG, Zug, Switzerland Circassia Pharmaceuticals plc (LSE:CIR), Oxford, U.K. CureVac GmbH, Tuebingen, Germany Cytonet GmbH & Co. KG...

...U.S. and Canadian Phase II SELICA III trial in infants and children ages <=5 years. Cytonet GmbH & Co. KG...

...90% Novel drug class; deal with Sanofi- Pasteur, the vaccines division of Sanofi (Euronext:SAN; NYSE:SNY) Cytonet GmbH & Co. KG...

...trial to evaluate infusions of human heterologous liver cells in 20 infant and pediatric patients. Cytonet GmbH & Co. KG...

...The COMP issued a positive opinion to grant Orphan Drug designation for Cytonet's human heterologous liver...
...1 and carbamoyl-phosphate synthetase-1 deficiency. The COMP is part of the European Medicines Agency (EMA). Cytonet GmbH & Co. KG...

...Orphan Drug designation for Cytonet's human heterologous liver cells for the treatment of ornithine-transcarbamylase deficiency. Cytonet GmbH & Co. KG...

...Vesta will manufacture Cytonet's liver cell therapies for up to two years. Cytonet's HHLivC heterologous liver...
...in liver failure by year end, valued the supply agreement in the millions of dollars. Cytonet GmbH & Co. KG...